Rodrigo Jiménez-Saiz1, Derek K Chu1, Talveer S Mandur1, Tina D Walker1, Melissa E Gordon1, Roopali Chaudhary1, Joshua Koenig1, Sarah Saliba1, Heather J Galipeau1, Adam Utley2, Irah L King3, Kelvin Lee2, Rachel Ettinger4, Susan Waserman5, Roland Kolbeck4, Manel Jordana6. 1. McMaster Immunology Research Centre (MIRC), Department of Pathology & Molecular Medicine, McMaster University, Hamilton, Ontario, Canada. 2. Departments of Immunology and Medicine, Roswell Park Cancer Institute, Buffalo, NY. 3. Department of Microbiology & Immunology, McGill University, Montreal, Quebec, Canada. 4. Department of Respiratory, Inflammation & Autoimmunity, MedImmune, Gaithersburg, Md. 5. Department of Medicine, McMaster University, Hamilton, Ontario, Canada. 6. McMaster Immunology Research Centre (MIRC), Department of Pathology & Molecular Medicine, McMaster University, Hamilton, Ontario, Canada. Electronic address: jordanam@mcmaster.ca.
Abstract
BACKGROUND: A number of food allergies (eg, fish, shellfish, and nuts) are lifelong, without any disease-transforming therapies, and unclear in their underlying immunology. Clinical manifestations of food allergy are largely mediated by IgE. Although persistent IgE titers have been attributed conventionally to long-lived IgE+ plasma cells (PCs), this has not been directly and comprehensively tested. OBJECTIVE: We sought to evaluate mechanisms underlying persistent IgE and allergic responses to food allergens. METHODS: We used a model of peanut allergy and anaphylaxis, various knockout mice, adoptive transfer experiments, and in vitro assays to identify mechanisms underlying persistent IgE humoral immunity over almost the entire lifespan of the mouse (18-20 months). RESULTS: Contrary to conventional paradigms, our data show that clinically relevant lifelong IgE titers are not sustained by long-lived IgE+ PCs. Instead, lifelong reactivity is conferred by allergen-specific long-lived memory B cells that replenish the IgE+ PC compartment. B-cell reactivation requires allergen re-exposure and IL-4 production by CD4 T cells. We define the half-lives of antigen-specific germinal centers (23.3 days), IgE+ and IgG1+ PCs (60 and 234.4 days, respectively), and clinically relevant cell-bound IgE (67.3 days). CONCLUSIONS: These findings can explain lifelong food allergies observed in human subjects as the consequence of allergen exposures that recurrently activate memory B cells and identify these as a therapeutic target with disease-transforming potential.
BACKGROUND: A number of food allergies (eg, fish, shellfish, and nuts) are lifelong, without any disease-transforming therapies, and unclear in their underlying immunology. Clinical manifestations of food allergy are largely mediated by IgE. Although persistent IgE titers have been attributed conventionally to long-lived IgE+ plasma cells (PCs), this has not been directly and comprehensively tested. OBJECTIVE: We sought to evaluate mechanisms underlying persistent IgE and allergic responses to food allergens. METHODS: We used a model of peanutallergy and anaphylaxis, various knockout mice, adoptive transfer experiments, and in vitro assays to identify mechanisms underlying persistent IgE humoral immunity over almost the entire lifespan of the mouse (18-20 months). RESULTS: Contrary to conventional paradigms, our data show that clinically relevant lifelong IgE titers are not sustained by long-lived IgE+ PCs. Instead, lifelong reactivity is conferred by allergen-specific long-lived memory B cells that replenish the IgE+ PC compartment. B-cell reactivation requires allergen re-exposure and IL-4 production by CD4 T cells. We define the half-lives of antigen-specific germinal centers (23.3 days), IgE+ and IgG1+ PCs (60 and 234.4 days, respectively), and clinically relevant cell-bound IgE (67.3 days). CONCLUSIONS: These findings can explain lifelong food allergies observed in human subjects as the consequence of allergen exposures that recurrently activate memory B cells and identify these as a therapeutic target with disease-transforming potential.
Authors: Andreas Radbruch; Gwendolin Muehlinghaus; Elke O Luger; Ayako Inamine; Kenneth G C Smith; Thomas Dörner; Falk Hiepe Journal: Nat Rev Immunol Date: 2006-09-15 Impact factor: 53.106
Authors: Donald Y M Leung; Hugh A Sampson; John W Yunginger; A Wesley Burks; Lynda C Schneider; Cornelis H Wortel; Frances M Davis; John D Hyun; William R Shanahan Journal: N Engl J Med Date: 2003-03-10 Impact factor: 91.245
Authors: Barbara J Hebeis; Karin Klenovsek; Peter Rohwer; Uwe Ritter; Andrea Schneider; Michael Mach; Thomas H Winkler Journal: J Exp Med Date: 2004-02-09 Impact factor: 14.307
Authors: Kyle J Bednar; Lakeya Hardy; Johanna Smeekens; Dharmendra Raghuwanshi; Shiteng Duan; Mike D Kulis; Matthew S Macauley Journal: J Vis Exp Date: 2018-10-25 Impact factor: 1.355
Authors: Markus M Xie; Qiang Chen; Hong Liu; Kai Yang; Byunghee Koh; Hao Wu; Soheila J Maleki; Barry K Hurlburt; Joan Cook-Mills; Mark H Kaplan; Alexander L Dent Journal: J Clin Invest Date: 2020-07-01 Impact factor: 14.808
Authors: Joseph J Dolence; Takao Kobayashi; Koji Iijima; James Krempski; Li Y Drake; Alexander L Dent; Hirohito Kita Journal: J Allergy Clin Immunol Date: 2017-12-14 Impact factor: 10.793
Authors: Bert Ruiter; Neal P Smith; Brinda Monian; Ang A Tu; Elizabeth Fleming; Yamini V Virkud; Sarita U Patil; Charles A Whittaker; J Christopher Love; Wayne G Shreffler Journal: J Allergy Clin Immunol Date: 2019-10-22 Impact factor: 10.793